Recent Finacing
Recent Raise
ReViral is a clinical-stage biopharmaceutical company developing oral RSV antivirals, including sisunatovir (RV521) in Phase 2 trials and an in-house N-protein replication inhibitor program in late preclinical development.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
